Chinese Classics Recitation Training in Subjective Cognitive Decline
NCT07463391, Not applicable, Recruiting, China Medical University Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Chinese Classics Recitation Training in Subjective Cognitive Decline | ClinicalTrials.gov |
| NCT number | NCT07463391 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | China Medical University Hospital | ClinicalTrials.gov |
| Conditions | Subjective Cognitive Decline (SCD), Subjective Cognitive Decline | ClinicalTrials.gov |
| Interventions | Memory training by Chinese Classics recitation | ClinicalTrials.gov |
| First posted | 2026-03-11 | ClinicalTrials.gov |
| Last updated | 2026-10-22 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in task-related brain activation measured by functional MRI | Baseline and 6 months | Unit of measure: Whole-brain blood-oxygen-level-dependent (BOLD) signal change (%) Detail Functional magnetic resonance imaging (fMRI) will be used to evaluate changes in task-related brain activation associated with the intervention. Whole-brain blood-oxygen-level-dependent (BOLD) signals will be analyzed using voxel-wise general linear modeling to identify activation patterns during task performance compared with resting baseline. First-level analyses will generate subject-specific contrast maps reflecting task-related neural activation. Group-level random-effects analyses will then be conducted to compare activation patterns between study groups and across time points. Statistical significance will be determined using a voxel-level threshold corrected for multiple comparisons using the false discovery rate (FDR). Effect sizes extracted from significant brain regions will be used for group-level comparisons. | ClinicalTrials.gov |
| Secondary | Resting-state electroencephalogram (EEG) spectral activity | Baseline and 6 months | Unit of Measure µV²/Hz (power spectral density) Detail Resting electroencephalogram (EEG) recordings will be acquired using a standard 21-electrode montage positioned according to the International 10-20 system. Electrode impedance will be maintained below 10 kΩ, with a minimum sampling rate of 256 Hz. Recordings will be performed in a quiet, dimly lit environment with participants seated comfortably and instructed to remain awake with their eyes closed. EEG preprocessing and analysis will be conducted using MNE-Python implemented in Python. The preprocessing pipeline will include re-referencing, resampling to 250 Hz, and band-pass filtering between 0.1 and 41 Hz. Artifact-free EEG signals will be segmented into non-overlapping 2-second epochs for subsequent spectral analysis. Quantitative EEG measures will be derived from the processed signals to characterize resting-state brain activity. | ClinicalTrials.gov |
| Secondary | Global Cognitive Function - MMSE | Baseline and 6 months | Outcome Measure Total score on the Mini-Mental State Examination (MMSE) Unit of Measure points Detail The MMSE is a widely used cognitive screening instrument assessing orientation, attention, memory, language, and visuospatial ability. Total score ranges from 0-30, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Secondary | Global Cognitive Function - MoCA | Baseline and 6 months | Outcome Measure Total score on the Montreal Cognitive Assessment (MoCA) Unit of Measure points Detail The MoCA evaluates multiple cognitive domains including executive function, memory, attention, language, abstraction, and orientation. Total score ranges from 0-30, with higher scores indicating better cognitive performance. | ClinicalTrials.gov |
| Secondary | Verbal Episodic Memory - RAVLT | Baseline and 6 months | Outcome Measure Total recall score on the Rey Auditory Verbal Learning Test (RAVLT) Unit of Measure points Detail The RAVLT assesses verbal learning and episodic memory through repeated recall of word lists across trials. Total recall score reflects the number of correctly recalled words, with higher scores indicating better memory performance. | ClinicalTrials.gov |
| Secondary | Executive Function - Stroop Test | Baseline and 6 months | Outcome Measure Interference completion time on the Stroop Color and Word Test Unit of Measure seconds Detail The Stroop test measures selective attention and cognitive control. The interference condition requires participants to name the ink color of incongruent color words. Lower completion time indicates better executive function. | ClinicalTrials.gov |
| Secondary | Working Memory - Digit Span | Baseline and 6 months | Outcome Measure Total span score on the Digit Span Test Unit of Measure points Detail Digit Span evaluates auditory attention and working memory through forward and backward recall of number sequences. Higher scores indicate better working memory capacity. | ClinicalTrials.gov |
| Secondary | Language Function - Boston Naming Test | Baseline and 6 months | Outcome Measure Total score on the Short Form (15 items) of the Boston Naming Test Unit of Measure points Detail The Boston Naming Test assesses confrontational naming ability. The short form contains 15 items, with total score ranging from 0-15, and higher scores indicating better language function. | ClinicalTrials.gov |
| Secondary | Dementia Severity - CDR | Baseline and 6 months | Outcome Measure Global score on the Clinical Dementia Rating (CDR) Unit of Measure scale score Detail The CDR is a clinician-rated scale evaluating cognitive and functional performance in dementia. Global score ranges from 0 (no impairment) to 3 (severe dementia). | ClinicalTrials.gov |
| Secondary | Vascular Cognitive Risk - Hachinski Score | Baseline | Outcome Measure Total score on the Hachinski Ischemic Score Unit of Measure points Detail The Hachinski Ischemic Score differentiates vascular from degenerative causes of cognitive impairment. Scores range from 0-18, with higher scores suggesting greater vascular contribution. | ClinicalTrials.gov |
| Secondary | Depressive Symptoms - GDS | Baseline and 6 months | Outcome Measure Total score on the Geriatric Depression Scale (GDS) Unit of Measure points Detail The GDS evaluates depressive symptoms in older adults. Higher scores indicate more severe depressive symptoms. | ClinicalTrials.gov |
| Secondary | Anxiety Symptoms - BAI | Baseline and 6 months | Outcome Measure Total score on the Beck Anxiety Inventory (BAI) Unit of Measure points Detail The BAI measures the severity of anxiety symptoms. Total score ranges from 0-63, with higher scores indicating greater anxiety. | ClinicalTrials.gov |
| Secondary | Cognitive Reserve - CRI-q | Baseline | Outcome Measure Cognitive reserve index score on the Cognitive Reserve Index questionnaire Unit of Measure index score Detail The CRI-q quantifies lifetime cognitive reserve based on education, occupational complexity, and leisure activities. Higher index scores indicate greater cognitive reserve. | ClinicalTrials.gov |
| Secondary | APOE genotype distribution | Baseline | Unit of Measure genotype category Detail Genomic DNA will be extracted from peripheral blood samples to determine the genotype of the APOE, a major genetic risk factor associated with cognitive decline and Alzheimer's disease. Participants will be categorized according to APOE genotype (e.g., ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4, ε4/ε4). | ClinicalTrials.gov |
| Secondary | Circulating inflammatory and stress biomarkers (IL-6, TNF-α, hsCRP, and cortisol) | Baseline and 6 months | Unit of Measure IL-6: pg/mL TNF-α: pg/mL hsCRP: mg/dL Cortisol: µg/dL Detail Peripheral venous blood samples will be collected after overnight fasting to quantify circulating inflammatory and stress-related biomarkers, including Interleukin-6, Tumor necrosis factor alpha, High-sensitivity C-reactive protein, and Cortisol. Blood samples will be collected in EDTA anticoagulant tubes and processed within 30 minutes by centrifugation at 2,000 × g for 10 minutes at 4 °C. Plasma will be aliquoted and stored at -80 °C until analysis. Cytokine concentration HsCRP concentrations will be measured using high-sensitivity immunoassays to evaluate systemic low-grade inflammation. Plasma cortisol levels will be measured using validated immunoassay methods to assess hypothalamic-pituitary-adrenal (HPA) axis activity and physiological stress responses. Changes in these biomarkers will be analyzed to explore potential inflammatory and neuroendocrine mechanisms associated with the intervention. | ClinicalTrials.gov |
| Secondary | Gut microbiota diversity (Shannon index) | Baseline and 6 months | Unit of Measure Shannon diversity index Detail Fecal samples will be collected to evaluate changes in gut microbial diversity associated with the intervention. Microbial community composition will be characterized using full-length 16S rRNA gene sequencing, enabling species-level taxonomic identification of intestinal microorganisms. Alpha diversity will be quantified using the Shannon diversity index, which reflects both species richness and evenness within the microbial community. Changes in Shannon diversity between baseline and follow-up will be analyzed to assess intervention-related alterations in gut microbiota diversity. | ClinicalTrials.gov |
| Secondary | Gut microbiota taxonomic composition | Baseline and 6 months | Unit of Measure Relative abundance (%) Detail Fecal microbiota composition will be analyzed using full-length 16S rRNA gene sequencing to determine the relative abundance of bacterial taxa at different taxonomic levels (e.g., phylum, genus, and species). Differential abundance analyses will be conducted to identify microbial taxa whose relative abundance changes over time or differs between study groups. | ClinicalTrials.gov |
| Secondary | Fecal metabolomic profiles related to the gut-brain axis | Baseline and 6 months | Unit of Measure Metabolite concentrations (µmol/g feces or relative abundance) Detail Fecal metabolomic profiling will be performed using Liquid chromatography-tandem mass spectrometry to quantify metabolites associated with gut microbiota-host interactions. Metabolites of interest include short-chain fatty acids, bile acids, tryptophan pathway metabolites, neurotransmitter precursors, and inflammation-related metabolites. These analyses will be used to investigate potential metabolic pathways linking gut microbial activity with cognitive and neurophysiological outcomes. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 42548715 | RESULT | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)